Business
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER ® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
By: investing_za
- Sep 16 2024
- 0
- 0 Views
ONLY AVAILABLE IN PAID PLANS